OTCMKTS:CSLLY CSL (CSLLY) Stock Forecast, Price & News $84.89 -0.47 (-0.55%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$84.59▼$87.3050-Day Range$84.48▼$91.0852-Week Range$83.30▼$110.25Volume86,567 shsAverage Volume83,948 shsMarket Capitalization$82.01 billionP/E RatioN/ADividend Yield1.40%Price TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest CSL MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth27.13%From $2.47 to $3.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently increased by 40.91%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.39%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 37.90% next year. This indicates that CSL will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 1.3 News and Social Media Coverage News SentimentCSL has a news sentiment score of -0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CSL this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added CSL to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.06% of the stock of CSL is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 27.13% in the coming year, from $2.47 to $3.14 per share.Price to Book Value per Share RatioCSL has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CSL (OTCMKTS:CSLLY) StockCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesSeptember 15, 2023 | americanbankingnews.comCSL (OTCMKTS:CSLLY) & Eagle Pharmaceuticals (NASDAQ:EGRX) Head-To-Head SurveySeptember 3, 2023 | msn.comASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…September 21, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 28, 2023 | finanznachrichten.deVifor International AG (CSL Vifor): Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelinesAugust 17, 2023 | finance.yahoo.comCSL Appoints Jeffrey Ball as First Chief Sustainability OfficerAugust 15, 2023 | startribune.comMinnesota halts court action against CSL Plasma for discriminating based on gender identityAugust 15, 2023 | msn.comCompliance brings end to state action against CSL Plasma for gender identity discriminationAugust 15, 2023 | msn.comCSL Limited NPATA of $2.38B, revenue of $13.31BSeptember 21, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 15, 2023 | fool.com.auEverything you need to know about the supersized CSL dividendAugust 14, 2023 | fool.com.auCSL share price in focus after FY23 profit guidance beatAugust 14, 2023 | reuters.comBiotech firm CSL's full-year profit rises on higher plasma collectionsAugust 14, 2023 | msn.comInflation, currency headwinds take toll on CSL's profitAugust 14, 2023 | afr.comCSL profit rebounds on plasma, blockbuster drug salesAugust 14, 2023 | wsj.comCSL Annual Profit Rises 8% at Constant FXAugust 3, 2023 | msn.comCSL (CMXHF) Price Target Decreased by 5.63% to 212.41August 3, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for CSL (CMXHF)August 1, 2023 | fool.com.auWhy did the CSL share price tumble in July?August 1, 2023 | markets.businessinsider.comWilsons Sticks to Their Buy Rating for CSL (CMXHF)July 27, 2023 | markets.businessinsider.comLoop Capital Markets Reaffirms Their Buy Rating on Carlisle Companies (CSL)July 26, 2023 | sports.yahoo.com2023 BMW M4 CSL video review | Autoblog GarageJuly 18, 2023 | markets.businessinsider.comJarden Remains a Buy on CSL (CMXHF)July 14, 2023 | fool.com.auIf I buy $10,000 of CSL shares right now, how much passive income will I receive?July 3, 2023 | fool.com.auWhy did the CSL share price sink 10% in June?June 22, 2023 | fool.com.auShould I quickly snap up CSL shares while they’re trading around the $280 mark?June 20, 2023 | bizjournals.comInside the launch: CSL Behring's $3.5M-per-dose gene therapy Hemgenix given to first hemophilia B patientJune 18, 2023 | markets.businessinsider.comUBS Remains a Buy on CSL (CMXHF)See More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSLLY Company Calendar Today9/21/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees30,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$10.56 billion Price / Sales7.77 Cash Flow$3.02 per share Price / Cash Flow28.15 Book Value$15.13 per share Price / Book5.61Miscellaneous Outstanding Shares966,130,000Free FloatN/AMarket Cap$82.01 billion OptionableNot Optionable Beta0.64 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 57)MD, CEO & Exec. Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 58)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Paul R. Perreault B.A. (Age 66)Strategic Advisor Comp: $2.89MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 62)BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel Christina HickieSr. Mang. of CommunicationsMs. Elizabeth Walker B.A. (Age 53)M.S., Exec. VP & Chief HR Officer Dr. Karen Etchberger (Age 65)Exec. VP of Quality & Bus. Services Ms. Jemimah BrennanHead of Communications - Asia PacificMr. William Campbell B.S. (Age 63)Exec. VP & Chief Commercial Officer More ExecutivesKey CompetitorsZoetisNYSE:ZTSGSKNYSE:GSKRegeneron PharmaceuticalsNASDAQ:REGNTakeda PharmaceuticalNYSE:TAKBristol-Myers SquibbNYSE:BMYView All Competitors CSLLY Stock - Frequently Asked Questions Should I buy or sell CSL stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSLLY shares. View CSLLY analyst ratings or view top-rated stocks. How have CSLLY shares performed in 2023? CSL's stock was trading at $97.54 at the start of the year. Since then, CSLLY stock has decreased by 13.0% and is now trading at $84.89. View the best growth stocks for 2023 here. Are investors shorting CSL? CSL saw a increase in short interest in August. As of August 31st, there was short interest totaling 3,100 shares, an increase of 40.9% from the August 15th total of 2,200 shares. Based on an average daily trading volume, of 140,500 shares, the days-to-cover ratio is currently 0.0 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.19 per share and currently has a dividend yield of 1.39%. Read our dividend analysis for CSLLY. What is CSL's stock symbol? CSL trades on the OTCMKTS under the ticker symbol "CSLLY." How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CSL's stock price today? One share of CSLLY stock can currently be purchased for approximately $84.89. How much money does CSL make? CSL (OTCMKTS:CSLLY) has a market capitalization of $82.01 billion and generates $10.56 billion in revenue each year. How many employees does CSL have? The company employs 30,000 workers across the globe. How can I contact CSL? CSL's mailing address is 45 Poplar Road, Parkville C3, 3052. The official website for the company is www.csl.com.au. The company can be reached via phone at (139) 389-1911, via email at bernard.ronchi@csl.com, or via fax at 61-3-9389-1434. This page (OTCMKTS:CSLLY) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.